List view / Grid view
29 July 2015 | By Victoria White
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin...
23 July 2015 | By Victoria White
The global market for type 2 diabetes mellitus therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021, driven primarily by rising disease prevalence and the continued uptake of recently approved and emerging branded treatments, according to business intelligence provider GBI Research.
22 July 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone implant as treatment options for some people with diabetic macular oedema...
15 July 2015 | By Victoria White
Lilly has released an Android version of its Glucagon Mobile application designed for caregivers and healthcare providers who support people with diabetes...
2 July 2015 | By Victoria White
Novo Nordisk has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany...
1 July 2015 | By Victoria White
Vitae has announced top-line efficacy results from the metformin arm of a trial of BI187004/VTP-34072 in the treatment of patients with type 2 diabetes...
30 June 2015 | By Victoria White
MSD recently announced the primary results of the TECOS trial, a placebo-controlled study of the cardiovascular safety of MSD’s DPP-4 inhibitor, sitagliptin...
Zealand has announced results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207.
29 June 2015 | By Victoria White
The CHMP has issued a positive opinion for the expanded use of Novo Nordisk’s Levemir (insulin detemir) in children with diabetes as young as one year old...
10 June 2015 | By Victoria White
Bayer has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., for EUR 1,022 million...
9 June 2015 | By Victoria White
Results of the ELIXA study assessing the cardiovascular safety of lixisenatide in adults with type 2 diabetes and high CV risk have been presented...
8 June 2015 | By Victoria White
A Phase II clinical trial testing the ability of the generic vaccine BCG to reverse advanced type 1 diabetes has received approval from the FDA...
8 June 2015 | By Victoria White
Lilly’s basal insulin peglispro has consistently demonstrated superior HbA1c reduction in people with type 2 diabetes compared to insulin glargine in trials...
8 June 2015 | By Victoria White
Sanofi has announced results from two extension studies where participants with diabetes received Toujeo or Lantus treatment for a total of 12 months...
8 June 2015 | By Victoria White
Phase 3b findings show adults with T2D treated with Xultophy demonstrate statistically significant reduction in HbA1c and a lower rate of hypoglycaemia...
